Implementing Minor Changes is Hard to Do Under Variations Regulation
This article was originally published in The Gold Sheet
Executive Summary
European generic drug makers say that it is difficult to implement Type IA changes under the variations regulation because of all the paperwork involved in submitting these changes to competent authorities. A 26 percent fee hike in filing variations is also making it more costly and difficult for manufacturers to justify making changes.